|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 453-462, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
JD Mitchell, R Lee, H Garan, JN Ruskin, DF Torchiana and GJ Vlahakes
The implantable cardioverter-defibrillator provides an alternative therapy
for medically refractory ventricular tachyarrhythmias in patients who are
not candidates for ventricular operations or in whom these operations have
failed. Currently, however, available devices have limitations. In this
report we describe our experience with a programmable, tiered therapy
device with anti-ventricular tachyarrhythmia pacing and VVI pacing
capabilities (Cadence V-100, Ventritex Inc., Sunnyvale, Calif.). This
device offers certain advantages compared with conventional implantable
cardioverter- defibrillators: (1) tiered, anti-ventricular tachyarrhythmia
therapy incorporating programmable, rate-adaptive burst pacing in addition
to energy-programmable cardioversion/defibrillation, (2) biphasic
cardioversion/defibrillation waveforms, resulting in lower defibrillation
thresholds, (3) the ability to abort therapy for nonsustained ventricular
tachyarrhythmias, (4) electrogram storage of detected events for later
retrieval and analysis, (5) noninvasive, device-generated programmed
stimulation for system testing, and (6) backup VVI pacing capability. Forty
patients (aged 14 to 79 years) with ventricular tachyarrhythmias refractory
to medical therapy received this device. The mean left ventricular ejection
fraction was 33% +/- 16%. Preoperative electrophysiologic testing revealed
inducible monomorphic ventricular tachyarrhythmia responsive to rapid
ventricular pacing in 36 patients (90%). An extrapericardial two-patch
configuration was used with either epicardial screw-in or bipolar
endocardial sensing/pacing wires. No operative mortality and no device-
related infection occurred. During a follow-up period of 16 +/- 7 months
(range 3 to 30 months), 38 patients remained active with the implanted
device; one patient died of congestive heart failure 4 months after
implantation, and the system was explanted in one patient who underwent
cardiac transplantation. In 33 patients a total of 1815 ventricular
tachyarrhythmias were detected that resulted in therapy. Rate-adaptive
burst pacing was used as the initial therapy in 1470 episodes and was
successful in 1352 instances (92%). Pacing-induced ventricular
tachyarrhythmia acceleration occurred in 4% of episodes. The remaining
ventricular tachyarrhythmia episodes were treated with cardioversion. In 18
patients (45%) cardioversion therapy was aborted after spontaneous
termination of ventricular tachyarrhythmia.(ABSTRACT TRUNCATED AT 400
WORDS)
ARTICLES
Experience with an implantable tiered therapy device incorporating antitachycardia pacing and cardioverter/defibrillator therapy
Department of Surgery, Massachusetts General Hospital, Boston 02114- 2696.
This article has been cited by other articles:
![]() |
A. Schaumann, F. v. z. Muhlen, B. Herse, B.-D. Gonska, and H. Kreuzer Empirical Versus Tested Antitachycardia Pacing in Implantable Cardioverter Defibrillators : A Prospective Study Including 200 Patients Circulation, January 13, 1998; 97(1): 66 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lee, J. D. Mitchell, H. Garan, J. N. Ruskin, B. A. McGovern, M. J. Buckley, D. F. Torchiana, and G. J. Vlahakes Operation for recurrent ventricular tachycardiaPredictors of short- and long-term efficacy J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 732 - 742. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |